Carbohydrate-based anti-inflammatories - Praxis/Fairchild

Drug Profile

Carbohydrate-based anti-inflammatories - Praxis/Fairchild

Latest Information Update: 31 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anutech
  • Developer Anutech; Praxis Pharmaceuticals
  • Class Carbohydrates
  • Mechanism of Action Insulin-like growth factor II stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetes mellitus; Multiple sclerosis; Ocular inflammation; Post-surgical adhesions; Psoriasis; Rheumatoid arthritis; Skin aging

Most Recent Events

  • 01 Aug 2001 This programme is still in active development for the management of facial wrinkles
  • 24 Nov 1999 Investigation in Diabetes mellitus in Australia (PO)
  • 24 Nov 1999 Investigation in Multiple sclerosis in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top